Early Use

This debate will examine the optimal timing of lutetium-PSMA therapy in the management of metastatic prostate cancer with a review of clinical trial evidence, patient selection criteria, and outcomes associated with different sequencing strategies. The discussion will address potential benefits of earlier intervention versus reserving lutetium-PSMA for more advanced disease stages. Our presenters will provide expert insight into how timing considerations may influence treatment outcomes in metastatic prostate cancer. Review emerging clinical trial data supporting earlier integration of PSMA-targeted radioligand therapy and its potential impact on disease control and survival outcomes, including discussion of patient selection, sequencing with existing systemic therapies, and safety considerations. Explore the rationale and challenges of moving lutetium-PSMA earlier in the treatment paradigm.